[
    {
        "agent": "User",
        "message": "This is the beginning of an individual meeting with Principal Investigator to discuss your research project.\n\nHere is the agenda for the meeting:\n\nYou are working on a research project to use machine learning to develop antibodies or nanobodies for the newest variant of the SARS-CoV-2 spike protein that also, ideally, have activity against other circulating minor variants and past variants. Your team previous decided to modify existing nanobodies to improve their binding to the newest variant of the SARS-CoV-2 spike protein. Your team has built three components of a nanobody design pipeline: ESM, AlphaFold-Multimer, and Rosetta. Each of these three tools can be used to score a nanobody mutation based on how the mutation affects binding to an antigen. Your goal is to start with an existing nanobody and iteratively add mutations to it to improve its binding to the newest variant of the SARS-CoV-2 spike protein, resulting in 24 modified nanobodies with one or more mutations. Please determine how to use ESM, AlphaFold-Multimer, and Rosetta in this iterative design process. An important constraint is that ESM can evaluate all potential mutations to a nanobody in 5 minutes while AlphaFold-Multimer takes 30 minutes per mutation and Rosetta takes five minutes per mutation. The whole iterative process should take no more than a few days to complete. Note that AlphaFold-Multimer must be run before Rosetta on each mutation since Rosetta requires the nanobody-antigen structure predicted by AlphaFold-Multimer. Additionally, note that ESM log-likelihood ratios are generally in the range of 5-10 (higher is better), AlphaFold-Multimer interface pLDDT confidence scores are generally in the range of 60-80 (higher is better), and Rosetta binding energy scores are generally in the range of -20 to -40 (lower is better).\n\nHere are the agenda questions that must be answered:\n\n1. In each iteration, what is the order of operations for evaluating mutations with ESM, AlphaFold-Multimer, and Rosetta?\n\n2. In each iteration, how many mutations (give a single number) will you evaluate with ESM, AlphaFold-Multimer, and Rosetta?\n\n3. At the end of each iteration, how will you weigh the ESM, AlphaFold-Multimer, and/or Rosetta scores (give a formula) to rank the nanobody mutations?\n\n4. At the end of each iteration, how many of the top-ranked mutations (give a single number) will you keep for the next round?\n\n5. How will you decide how many iterations of mutations to run?\n\n6. After all of the iterations are complete, how exactly (step-by-step) will you select the final set of 24 modified nanobodies from across the iterations for experimental validation?\n\nPrincipal Investigator, please provide your response to the agenda."
    },
    {
        "agent": "Principal Investigator",
        "message": "To address the agenda questions, we will design an iterative process for optimizing nanobodies using ESM, AlphaFold-Multimer, and Rosetta. Here\u2019s how we plan to proceed:\n\n1. **Order of Operations in Each Iteration:**\n\n   - **Step 1:** Use ESM to score all potential single-point mutations of the current nanobody. Given the speed of this tool, ESM will provide an initial screening of mutations based on log-likelihood ratios.\n   - **Step 2:** Select a subset of the top mutations based on ESM scores to proceed with structure prediction.\n   - **Step 3:** Use AlphaFold-Multimer on the top-ranked mutations from ESM to predict the structural impact and calculate the interface pLDDT confidence scores.\n   - **Step 4:** Use Rosetta to refine and evaluate the binding energies of AlphaFold-Multimer predicted structures.\n\n2. **Number of Mutations Evaluated in Each Iteration:**\n\n   - **ESM:** Evaluate all possible mutations (since it is computationally inexpensive and quick).\n   - **AlphaFold-Multimer and Rosetta:** Given the time constraints, evaluate approximately 10 mutations per iteration, balancing between computational feasibility and diversity of mutations.\n\n3. **Weighing and Ranking Mutations:**\n\n   - Create a composite score for each mutation using a weighted formula that balances the results from each tool:\n     \\[\n     \\text{Composite Score} = w_1 \\times \\text{(ESM Score)} + w_2 \\times \\text{(AlphaFold-Multimer Score)} - w_3 \\times \\text{(Rosetta Score)}\n     \\]\n   - Weights (\\(w_1, w_2, w_3\\)) can be adjusted based on their relative importance. An initial choice could be \\(w_1 = 0.3\\), \\(w_2 = 0.4\\), \\(w_3 = 0.3\\) to give more weight to structural and binding predictions.\n\n4. **Number of Top-Ranked Mutations Kept for Next Round:**\n\n   - Keep the top 3 mutations from each iteration to introduce diversity while maintaining efficiency in the iterative process.\n\n5. **Deciding Number of Iterations:**\n\n   - Plan for approximately 4 iterations. This allows for a thorough exploration of the mutation space within the computational time constraints, while progressively improving the nanobody design.\n\n6. **Selection of Final 24 Modified Nanobodies:**\n\n   - **Step 1:** Compile all mutations retained from each iteration.\n   - **Step 2:** Calculate and rank the composite scores for all these mutations.\n   - **Step 3:** Select the top 24 unique mutations with the highest composite scores for experimental validation. Ensure diversity by checking for structural novelty and different binding sites if applicable.\n   - **Step 4:** Consult with the team to review the final selection to ensure alignment with experimental feasibility and potential for broad variant coverage.\n\nThis strategy should efficiently guide the nanobody optimization process within the given constraints and maximize the likelihood of achieving nanobodies with strong binding across variants."
    }
]